IMPORTANCE Aphasia is a debilitating language disorder for which behavioral speech therapy is the most efficient treatment, but therapy outcomes are variable and full recovery is not always achieved. It remains unclear if adjunctive brain stimulation (anodal transcranial direct current stimulation [A-tDCS]) applied during aphasia therapy can improve outcomes.
T he National Institute on Deafness and Other Communication Disorders estimates that at least 1 million people experience poststroke aphasia in the United States.
1 Considerable evidence suggests behavioral aphasia treatment is effective in improving communication and quality of life in individuals with long-term aphasia. [2] [3] [4] Nevertheless, even with therapy, aphasia recovery is often minimal.
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During the past decade, several pilot studies have indicated adjunctive transcranial direct current stimulation (tDCS) may improve the effects of aphasia treatment. [6] [7] [8] [9] Transcranial direct current stimulation is a noninvasive method that uses an electrical current (1-2 mA) typically induced between 2 electrodes placed on the scalp. The specific neural mechanism underlying tDCS modulation is not completely understood, but anodal tDCS (A-tDCS) has been shown to generally enhance cortical activity, whereas cathodal stimulation usually has the opposite effect.
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Based on promising pilot data, 6,7 we carried out a doubleblinded randomized clinical trial to test whether further investigation of the efficacy of adjunctive A-tDCS combined with aphasia therapy to manage long-term poststroke aphasia is futile. We used a futility design in which the null hypothesis assumed a benefit of A-tDCS compared with sham tDCS (S-tDCS), and the alternative hypothesis assumed no difference between A-tDCS and S-tDCS. [11] [12] [13] Instead of demonstrating efficacy, the futility design permits the identification of treatments that do not warrant further investigation, demonstrating a lack of superiority. Treatments for which a lack of superiority cannot be demonstrated are then suitable candidates for further investigation with traditional superiority trial designs.
Methods

Patients
The trial protocol is available in Supplement 1. Patients were enrolled from August 2012 to March 2017, and analyses began in April 2017. Patient inclusion criteria was single-event ischemic stroke in the left hemisphere, longer than 6 months poststroke, between the ages of 25 and 80 years, previously right-handed, aphasia as confirmed using the Western Aphasia Battery-Revised (WAB-R 14 ), no magnetic resonance imaging (MRI) contraindications, and able to achieve at least 65% accuracy on a screening version of the aphasia treatment task (see details in the section titled Aphasia Treatment). The correlation between performance on the screening version of the aphasia treatment task and overall aphasia severity, measured as the Aphasia Quotient (AQ; a 100-point scale) on the WAB-R, was r =0.27 ,P = .02. Exclusion criteria was history of brain surgery, seizures during the previous 12 months, sensitive scalp (per patient report), more than 80% naming accuracy on the Philadelphia Naming Test (PNT), 15 and unable to overtly name at least 5 of 80 items during pretreatment functional MRI (fMRI) sessions. The study was approved by the institutional review boards at the University of South Carolina and the Medical University of South Carolina, where all data collection occurred. All participants provided written consent for study inclusion. An independent data safety monitoring board assessed safety and quality of the study.
Randomization and Blinding
Eligible individuals were randomized to either A-tDCS or S-tDCS coupled with a computerized behavioral treatment of anomia. 16 The Biostatistics Core at the Data Coordination
Unit (located at Medical University of South Carolina) programmed the randomization algorithm, which used the minimal sufficient balancing method to prevent imbalances in site, baseline age, aphasia type, and aphasia severity. 17 Study participants and all members of the study team (the speech language pathologists [SLPs] who administered clinical testing and treatment, study coordinators, and principal and coinvestigators) were blinded to the intervention assignment.
Transcranial Direct Current Stimulation
Brain stimulation relied on a constant current stimulator (Phoresor II PM850; Iomed Inc) that provided 1 mA of A-tDCS stimulation induced between two 5 × 5 cm saline-soaked sponges (electrodes). The selection of 1 mA current was consistent with our previous pilot studies and our in-house data suggesting that 1 mA is less likely to induce scalp pain compared with 2 mA, a current strength also commonly used in the literature. The anode electrode was placed on the left scalp over a targeted cortical region and the cathode electrode was placed on the contralateral supraorbital frontal scalp region (above the right eyebrow). All participants completed 2 MRI sessions at baseline, which included T1-and T2-weighted structural MRI and a picture naming fMRI protocol. As our goal was to stimulate surviving eloquent tissue, the anodal electrode was placed over the temporal lobe region with the highest naming related activation on the fMRI (for more details on the fMRI setup, see the study by Findings This randomized clinical trial used a futility design to test adjunctive anodal tDCS during speech therapy among 74 patients with long-term aphasia who received 3 weeks of therapy coupled with either anodal tDCS or sham tDCS. The magnitude of pretreatment to posttreatment improvement using anodal tDCS compared with sham did not find evidence that further investigation of anodal tDCS was futile.
Meaning Anodal tDCS during speech therapy should be further assessed for treatment of patients with aphasia.
carefully fitted on the patient prior to the start of each tDCS administration to accurately position the anode electrode in the same area from one day to the next. Following positioning, the cap was removed and the electrodes were held in place with self-adhesive bandages. The scalp coordinates where the left hemisphere electrode was placed for each participant can be seen in eFigure in Supplement 2. The A-tDCS stimulation was started at the beginning of the behavioral treatment sessions and remained active during the first 20 minutes of the 45-minute treatment session. The 20-minute stimulation period was chosen based on our preliminary studies that suggested it was well tolerated by participants and was not associated with serious adverse events. Typically, participants in tDCS studies report itching or tingling sensation under the electrodes during the first 15 to 20 seconds of stimulation; however, this sensation is transient. 10 To blind patients as to whether they were receiving active or sham tDCS, the same scalp sensation was induced during the start of the S-tDCS sessions when the tDCS stimulation was applied to the scalp for 30 seconds but then the current was gradually decreased over 15 seconds as the current was shunted to a load resistor. In-house hardware was used to mask treatment type (A-tDCS vs S-tDCS) for both patients as well as the SLPs. The described randomization scheme directed an independent technician to set the position of an internal switch on the sham controller. Neither the patient nor SLP was aware of the position and the SLP did not know which switch position (X or Y) was the sham position. Treatment type was encoded in the software so the SLP only needed to enter a patient and session number to start stimulation without knowing whether those specific numbers were assigned to A-tDCS or S-tDCS. Following each individual's treatment, a technician validated whether the tDCS device was delivering anodal or sham stimulation.
Aphasia Treatment
The aphasia treatment was performed through a computerized task that involved matching pictures depicting common objects with words that were heard (via headphones) and seen (the face of the speaker below the nose is shown on the computer screen). 7, 16 Patients were instructed to press a green response button if the picture and spoken word matched and a red response button if they did not. Incorrect matches included a semantic foil, a phonological, or an unrelated word. Half of the pairs represented a correct match. Immediate feedback was provided following each response, and task accuracy was displayed on the computer screen at the end of each session to allow patients to monitor their progress. A total of 160 low-, medium-, and high-frequency words not included on the PNT were targeted in the computerized treatment task. Most participants completed treatment in clinics, whereas a few received treatment at their place of residence.
Procedures
The initial screening visit occurred over 2 days. Participants underwent a medical history and comprehensive neurologic, language, and cognitive testing using the following tests: Na- 
Outcomes
The primary end point was the change in the number of correctly named common objects at 1 week posttreatment, measured using a portion (Naming 80) of the trained items from the treatment plus the PNT. Only some treatment items were selected to decrease assessment time at each time. The PNT is commonly used in research studies to assess anomia and includes 175 pictures depicting mid-frequency to highfrequency nouns, which patients are instructed to name 1 item at a time. Naming accuracy was scored based on PNT scoring guidelines.
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The pretreatment to posttreatment change was computed as the difference between the mean of the 2 pretreatment assessments and the mean of the 2 posttreatment sessions. Secondary outcomes included change in the number of correctly named items at 4 and 24 weeks posttreatment.
Statistical Analysis
The primary null hypothesis assumed A-tDCS would lead to at least a 1.5-item greater improvement in correct naming compared with S-tDCS. The alternative hypothesis assumed no difference between the 2 conditions. The statistical hypotheses were H 0 :μ A −μ S ≥ 1.5 vs H A :μ A −μ S <1.5, in which μ A was the expected change (pretreatment and 1-week posttreatment) in the number of correctly named items in the A-tDCS group and μ S was the expected change in the S-tDCS group. If the null hypothesis was rejected at a 1-sided significance level of .10, then A-tDCS would be unlikely to be effective for aphasia management, and further study of A-tDCS would be considered futile.
In preliminary studies with 5 treatment sessions, the mean difference between the A-tDCS and S-tDCS groups in naming accuracy was 2.5 words (change from baseline; pooled SD 2.6), and the S-tDCS group mean change was 4.0. 6, 7 To estimate the sample size, we assumed the mean change from baseline to 1-week posttesting for the A-tDCS group under the null hypothesis of nonfutility to be μ A =μ S +1.5=4+1.5=5.5. Under these assumptions (H 0 :μ A = 5.5 and H A :μ A = 4)with33in-dividuals per group, a 2-sample t test with a .10 1-sided significance level will have 85% power to reject the null hypothesis that the A-tDCS treatment is 1.5 points better than S-tDCS and declare futility when the A-tDCS treatment comes from a distribution with mean change of 4 (assuming the pooled SD is 2.6). Assuming a dropout rate of 5%, the required sample size was inflated from 33 to 37 per group to account for the effect of the dropouts in the intent-to-treat analysis using an inflation factor.
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The primary analysis was an intent-to-treat analysis and was adjusted for enrolling site and baseline aphasia severity measured as the AQ from the WAB-R. Missing data (for 1 patient) were imputed using multiple imputation, assuming a monotone missing mechanism, missing at random, and used 10 imputed data sets (SAS PROC MI and MIANALYZE). All analyses were conducted in SAS version 9.3 (SAS Institute Inc).
Results
Between August 2012 and April 2017, 89 patients were screened, and 74 patients (83%) were enrolled ( Figure 1 ). Thirtyfour individuals (41%) were randomized to receive A-tDCS, and 40 (48%) were randomized to receive S-tDCS. The last individual was randomized during April 2017. On May 25, 2017, the study database was partially locked, up to and including the 1-week posttreatment visits. Once all follow-up visits were completed, the database was locked on November 8, 2017. One individual withdrew consent after completing posttreatment assessments, and 1 individual was lost to follow-up after the 11th treatment session. Therefore, the primary outcome was missing for only 1 individual.
Two individuals who had hemorrhagic stroke rather than ischemic stroke were erroneously enrolled, both in the S-tDCS group. As this was an intent-to-treat trial, their data were included in the primary analyses. Baseline demographic and clinical characteristics were similar between the 2 treatment arms ( Table 1 ). The enrolled individuals had a mean (SD) age of 60 (10) years, had 15 (2) years of education, and were 44 (40) months from stroke onset. There were 52 men (70%) and 62 non-Hispanic white individuals (84%). Most were retired or not employed (59 [80%]). Broca aphasia was the most common aphasia type (39 [52.7%]). Several of the clinical characteristics were somewhat higher on average at baseline in the A-tDCS group, although not statistically significantly different from the S-tDCS group. eTable in Supplement 2 compares the distribution of aphasia types and severity in the current trial with a large national cohort of patients with long-term aphasia (AphasiaBank  26 ) . Overall, the current trial included more severe aphasia than the AphasiaBank cohort as indicated by a lower WAB-R AQ and has greater rate of Broca aphasia and fewer participants with anomic aphasia. To ensure proper blinding, each patient and clinician was asked to guess the stimulation type at the end of their treatment phase. Patients' guessing accuracy was 47.9% and clinicians' guessing accuracy was 54.2%, meaning that each group's accuracy was essentially at chance guessing. All but 1 participant improved on the treatment task as suggested by greater task accuracy on the last treatment session compared with the first treatment session (overall mean [SD] change in accuracy was 10.3 [7.9]), suggesting that patients were actively participating in the aphasia therapy and were compliant with the task. Table 2 demonstrates the results from the primary analysis, which is based on the intent-to-treat sample (n = 74). The P value of .90 indicates a failure to reject the null hypothesis, and there is no evidence that further investigation of A-tDCS would be futile as an adjunctive treatment for poststroke aphasia. Baseline aphasia severity (AQ) was correlated with the overall improvement in naming at 1 week posttreatment (Pearson ρ=0.29,P = .01). The adjusted mean (SE) 1-week posttreatment change was an increase in 13.9 (2.4) (95% CI, 9.0-18.7) items correctly named for the A-tDCS group and 8.2 (2.2) (95% CI, 3.8-12.6) for the S-tDCS group (mean [SE] difference of 5.7 [3.3]; 95% CI, −0.9 to 12.3; Figure 2 ). The results of an unadjusted, completers-only analysis excluding the 2 ineligible patients with hemorrhagic stroke (n = 71) of the primary outcome were consistent with the primary analysis of the intentto-treat sample (test of H 0 :μ A −μ S ≥ 1.5; t statistic, 1.35; 1-sided P = .91). Because of an imbalance at baseline on the primary outcome, a sensitivity analysis was conducted and the primary outcome was adjusted for baseline PNT + Naming 80 score, treatment site, and baseline AQ; the results were consistent with the primary analysis (test of H 0 :μ A −μ S ≥ 1.5; t statistic, 1.2; 1-sided P = .89). At 4 weeks posttreatment, the adjusted mean (SE) change from baseline in correct naming was an increase in 16.8 (2.8) correctly named (95% CI, 11.3-22.4) for A-tDCS and 9.4 (2.5) (95% CI,4.4-14.5) for S-tDCS (intent-totreat sample, adjusted for site and baseline aphasia severity) (test of μ A −μ S ≥ 1.5, 1-sided P = .94). At 24 weeks posttreatment, the adjusted mean (SE) change from baseline in correct naming was 14.9 (3.7) (95% CI, 8.8-21.1) for A-tDCS and 7.1 (3.3) (95% CI, 1.59-12.0) for S-tDCS (intent-to-treat sample, adjusted for site and baseline AQ) (test of H 0 :μ A −μ S ≥ 1.5, 1-sided
The treatment sessions were well tolerated. There were 2 enrolled individuals (3%) who did not receive all 15 treatment sessions (1 A-tDCS individual and 1 S-tDCS individual). The A-tDCS individual dropped out after treatment session 11. The S-tDCS individual experienced a seizure during the course of the trial, and treatment sessions were subsequently discontinued. Importantly, the individual who experienced the seizure was in the S-tDCS group, thus receiving sham stimulation.
There were 8 mild, nonserious adverse events (Table 3) , and there were no statistically significant differences between treatment groups for number of adverse events. Two individuals (6%) in the A-tDCS group experienced transient scalp redness/irritation (erythema) compared with none in the S-tDCS group. On the Wong-Baker FACES Pain Rating Scale, most often individuals reported no hurt: 94% (n = 476) in A-tDCS vs 86% (n = 511) in S-tDCS. The highest pain rating reported was 3 (indicating "hurts even more"), which was reported 4 times by 2 individuals (3%), both in the S-tDCS group. Vital signs were similar between groups for all treatment sessions.
Discussion
This study found no evidence that further study of adjunctive A-tDCS would be futile when combined with behavioral aphasia treatment. Given that we failed to reject the null hypothesis, that A-tDCS results in better treatment outcome than S-tDCS, the results suggest a larger trial may be warranted to further evaluate the effects of A-tDCS on aphasia treatment. The current results, along with our previous smaller pilot studies, 6,7 lend support to the underlying scientific hypoth- 
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Transcranial Direct Current Stimulation to Treat Aphasia After Stroke esis that adjunctive A-tDCS improves the outcomes of longterm aphasia treatment among individuals with poststroke aphasia, although further research is needed to test this definitively. Breitensten and colleagues 2 found that baseline stroke severity was associated with aphasia treatment outcome in which patients with more severe aphasia were less likely to respond. In the current trial, stroke severity, as assessed by the National Institutes of Health Stroke Scale, and the distribution of aphasia types, was comparable across the 2 study arms. However, there were several numerical differences in aphasia severity at baseline, all of which were not statistically significant, but the A-tDCS group was nominally better at baseline. However, the difference in the primary outcome remained even after adjusting for baseline differences in aphasia severity; thus, the observed difference is unlikely to be due to differences in baseline status. Naming was chosen as the primary outcome because anomia is present in all types of aphasia regardless of severity, and naming is commonly targeted in aphasia treatment to improve word retrieval and speech production. Although naming is not synonymous with speech production, naming impairment is directly associated with poor quality of life in patients with aphasia. 27 Yet, other pilot studies have also suggested adjunctive A-tDCS during aphasia treatment can result in greater improvements in functional communication abilities. 28 Whereas the standard of care for aphasia is behavioral speech therapy, 29 a minimal clinically important difference in naming accuracy has not been established for Englishspeaking patients. Specifically, it is not clear what amount of improvement in language processing patients would consider as enhancement of daily functioning, although we believe that even 1 to 2 words' improvement could be meaningful to some patients who have very limited speech output. At all 3 times posttreatment, the change from baseline in A-tDCS was nearly twice as large as that of the S-tDCS group, an effect that is likely to be meaningful. Nevertheless, based on the current data, we cannot assume the treatment effect demonstrated here would generalize to functional communication abilities. The treatment task used here emphasizes lexical-semantic processing and was selected because it has been shown to improve naming in persons with aphasia. 6, 7, 16 Most importantly, it enabled controlling of equal treatment time and intensity across the 2 study arms. There are other forms of aphasia therapy that are probably equally or more effective for improving naming, and the purpose of the current trial was not to confirm the effectiveness of aphasia therapy but to assess the adjuvant benefit of A-tDCS when combined with a proven form of aphasia therapy. Based on first principles, we can see no reason why the effect of A-tDCS should be treatment-type-specific suggesting that an effect of A-tDCS would likely generalize to other kinds of aphasia treatment approaches. However, this may need to be verified in future studies. It is also important that future studies assess factors such as the length of the aphasia treatment session in relation to the optimal tDCS duration and intensity as we do not know whether and how much the current results are specific to the current study protocol.
Given that the total number of A-tDCS sessions administrated here was more than 500, the rate of adverse events shown in this study would have to be considered very low. Erythema on the scalp occurred exclusively in the A-tDCS group (6% of individuals) but was mild and resolved within 1 to 2 days. These data suggest A-tDCS administered at 1 mA for 20 minutes is safe and has minimal adverse effects. A recent Cochrane review of tDCS studies in aphasia also reported no serious adverse events for any studies included in the review.
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Limitations
The current study was not powered for superiority analyses to compare A-tDCS with S-tDCS. Therefore, we cannot conclude that A-tDCS is effective for boosting the effect of aphasia even though the magnitude of naming improvement was numerically greater with A-tDCS compared with S-tDCS. It is also a limitation that we cannot definitively determine that the naming improvements translate to improvements in quality of life.
Conclusions
The results reported here suggest that adjunctive A-tDCS is worthy of further study in a randomized clinical trial as an option to enhance the effect of behavioral treatment of aphasia in stroke. They provide the necessary basis to inform a definitive trial to assess A-tDCS as a treatment option for aphasia. 
SELECTION OF PATIENTS
Patients in this study will have chronic stroke-induced aphasia. Diagnostic evaluations will be conducted during the patients' initial visit to confirm aphasia diagnosis. Patients currently receiving speech and language treatment (apart from aphasia support groups) will be required to temporarily discontinue involvement until study completion. !
Patient Inclusion Criteria
Patients must satisfy the following inclusion criteria to be considered eligible for entry into this study: 1. Patients must be willing and able to give informed consent.* 2. Patients must be willing and able to comply with study requirements. 3. Patients must be between 25-and 80-years of age. 4. Patients must be native English speakers. 5. Patients must be pre-morbidly right-handed. 6. Patients must have sustained a one-time stroke in the left-hemisphere. 7. Patients must be greater than 6-months post-stroke. 8. Patients must have an aphasia diagnosis as confirmed by the Western Aphasia BatteryRevised. 9. Patients must be MRI-compatible (e.g., no metal implants, not claustrophobic, etc.). 10. Patients must achieve at least 65% accuracy on naming task during screening.
Patient Exclusion Criteria
Patients with any of the following characteristics will not be eligible for entry into this study: 1. History of brain surgery 2. Seizures during the previous 12 months 3. Use of medications that lower the seizure threshold (e.g., Ritalin, Adderall, Buproprion, etc.) 4. Sensitive scalp (per patient report) 5. Able to overtly name more than an average of 140 out of 175 items during the pre-treatment picture naming test (Philadelphia Naming Test) during Visits 2 or 3 6. Unable to overtly name at least a total of 5 out of 80 items during the pre-treatment fMRI sessions during Visits 2 or 3 *The investigators in charge of this study are speech-language pathologists who have expertise in assessing, treating, consenting, and communicating with adults with speech-language impairment of many types and severities. It is important to note that aphasia is an impairment of speech-language, not intelligence, and that most often, in the absence of comorbid impairment(s), competence is not reduced but only masked by the speech-language impairment. The consent document is reviewed thoroughly, with verification questions asked frequently to ensure that the potential participant and his or her caregiver understand the scope of the research project. Only participants who clearly understand the research and are able to indicate consent to participate can be enrolled in this study. Caretakers, family, or friends must be present during consent approval, but they cannot consent for the participant. If written consent is not possible, they may act as witnesses for verbal consent. Crucially, because this population is not devoid of language and can make their wants, needs, and preferences known (either via impaired speech or via alternative communication modalities such as gestures, writing, etc.), participants who have the ability to consent also have the ability to inform the investigators that they wish to cease their participation if necessary.
STUDY PROCEDURES 2.1 Study Procedures Overview
After informed consent is received, a neurological examination will be performed and multiple screening assessments will be conducted including a tDCS and MRI safety screening (see below). If the patient passes the initial screening portion, speech and language diagnostic testing will be conducted during the same visit (Visit 1). During the next two visits (Visits 2 and 3), patients will undergo baseline assessments of naming ability and connected speech, and structural and functional MRI examinations. The fourth visit will include collection of blood sample, electrode positioning and tDCS treatment administration. Patients will receive 15 sessions (Visits 4-18) of tDCS treatment administration. At the beginning of Visit 4, eligible patients will be randomized to receive either A-tDCS (1 mA) or S-tDCS (placebo) for 15 consecutive weekdays (20-min per each 45-min behavioral treatment session). A computerized anomia treatment will be coupled with the stimulation. The computerized treatment task will be 45-minutes in total length, so that it will commence at the same time as the tDCS administration and continue for another 25-minutes after the tDCS has ceased. To assess cardiovascular arousal, blood pressure and heart rate will be measured before and after each session. Additionally, discomfort ratings will be recorded following the end of each session using the Wong-Baker FACES Pain Rating Scale and a weekly neurological exam will be administered by a neurologist. Utilizing a computerized picture naming assessment (which combines the 175 items from the PNT and 80 treated items) of trained and untrained nouns, all patients will be assessed at 8 different time points throughout the experiment: twice at baseline (Visit 2 and 3), twice one week following the fifteenth (and final) treatment session (Visit 19 and Visit 20) , twice at 4 weeks follow-up (Visit 21 and Visit 22), and twice at 6 months follow-up (Visit 23 and Visit 24).
Procedures for Screening (Visit 1)
The following procedures will be performed:
1. Obtain written informed consent: o A signed and dated informed consent form will be obtained from each patient before conducting any screening procedures. Patients will be then be assigned a temporary identification number for the purposes of initial screening. o All research staff authorized to obtain informed consent will have completed the Miami CITI course in the Responsible Conduct of Research and Protection of Human Subjects prior to their involvement with the study. Furthermore, they will be oriented to the study and trained by the study PI and study co-investigators who have all had extensive training and experience in the ethical and practical aspects of informed consent procedures. 7. Administer naming screen used to verify that patients comprehend task requirements o Refer to computer setup for the treatment for information regarding the computerized naming assessment. A shortened naming screen (identical set up and response requirements) will be presented to patients. Patients will get three attempts to achieve at least 65% accuracy on the task. If a patient is unable to reach this level of accuracy, study enrollment will be discontinued.
Procedures for Diagnostic Testing (Visit 1)
If the patient passes the screening portion, diagnostic testing will be conducted during the same visit. The following diagnostic testing procedures will be performed:
1. Administer the Western Aphasia Battery-Revised (WAB-R): o The WAB-R will characterize the patients' overall language impairment through the evaluation of the main clinical aspects of language functioning, including speech content, speech fluency, auditory comprehension, repetition, and naming. The WAB-R allows for the differentiation of these specific language abilities, as well as the classification of aphasia type. The WAB-R also yields a composite score, the Aphasia Quotient, which provides an overall measure of severity, in which lower scores denote more severe aphasia (Kertesz, 2007) . Speechlanguage pathologists (SLPs) will refer to the manual for explicit instructions regarding administration and scoring procedures. Administration time will range between 30-45 minutes.
Administer the Boston Naming Test-Second Edition (BNT):
o The BNT represents a measure of object naming abilities from a corpus of 60 line drawings. Object names are ranked along a continuum, with easier, more higherfrequency words appearing at the beginning of the test and more difficult, lowerfrequency words appearing near the end. To eliminate patient frustration, the BNT implements a ceiling effect so that once the patient incorrectly names eight items in a row, testing will cease, with the assumption that (s)he would not correctly name the upcoming, more difficult words (Kaplan, Goodglass, & Weintraub, 2001 ). SLPs will refer to the manual for explicit instructions regarding administration and scoring procedures. Administration time will range between 5-20 minutes.
3. Administer Subtest 6 from the Apraxia Battery for Adults-Second Edition (ABA-2) for Apraxia of Speech Rating Scale (ASRS) scoring: o Subtest 6 (Inventory of Articulation Characteristics) of the ABA-2 is a rating scale, in which speech characteristics are evaluated on 15 different items (e.g., the patient exhibits: marked difficulty initiating speech; highly inconsistent errors; or visible/audible searching). The range of scores on Subtest 6 is 0-15, where a score above 5 is thought to signify the presence of apraxia of speech, an impairment in the programming of movements for the purpose of speaking without neuromuscular deficit (Dabul, 2000) . Higher scores indicate more severe apraxia of speech. SLPs will refer to the manual for explicit instructions regarding administration and scoring procedures. Administration time will range between 10-15 minutes.
Administer the Pyramids and Palm Trees Test (PPTT)
o The PPTT is a test of semantic processing. This test assesses the degree to which a patient can access meaning from pictures and words. Information from the test will help determine whether a patient's difficulty in naming or pointing to a named picture is due to a difficulty in retrieving semantic information from pictures, or a difficulty in retrieving semantic information from words, or, in the case of a naming failure, a difficulty in retrieving the appropriate spoken form of the word (Howard & Patterson, 1992) . SLPs will refer to the manual for explicit instructions regarding administration and scoring procedures. Administration time will range between 10-20 minutes.
Administer the abstract reasoning sub-test of the WAIS
o This test is a measure of nonverbal reasoning. The WAIS sub-test was constructed to test whether individuals are able to reason by analogy and adopt this way of thinking as a consistent method of inference. SLPs will refer to the manual for explicit instructions regarding administration and scoring procedures. Administration time will range between 15-20 minutes.
Procedures for MRI Examination (Visits 2, 3)
1. Run the patient on a 10-minute fMRI exam during visits two and three: o Instruct the patient to overtly name pictures representing nouns (n = 40) once they appear on the screen and to say nothing when abstract pictures (n= 20) appear on the screen o The pictures will be presented for 2 s each on a back-projected mirror located on top of the head coil o A non-ferrous microphone will be placed 1-3 cm from the patient's mouth and used to record naming attempts, which will be recorded with sufficient clarity for off-line scoring by a trained speech-language pathologist 2. Run the patient on high-resolution anatomical MRI scans during Visit 2: o Instruct the patient to do nothing during these scans
Procedures for the Computerized Naming Assessments (Visits 2, 3, 19-24)
The following procedures will be performed during Visits 2, 3, and 19-24:
1. Turn on the laptop computer and position in front of the patient 2. Set up and start internal web-camera for audio-visual recording. 2) Fisher exact test suggests a statistically significant difference in distribution of aphasia types between the two samples P = .001. Considerably greater proportion of participants had Broca aphasia and smaller proportion had anomic aphasia in the current trial. Overall, the current trial included more severe aphasia than the AphasiaBank cohort, as indicated by a lower WAB aphasia quotient (AQ) (two-sample t test P < .001). Abbreviations: SD, standard deviation; WAB AQ, Western Aphasia Battery Aphasia Quotient.
